Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Maria Gabriella RaimondoMartina BiggioggeroLavinia Agra ColettoAndreas RammingRoberto Felice CaporaliEnnio Giulio FavalliPublished in: Expert review of clinical pharmacology (2021)
The phase II and phase III randomized controlled trials (RCTs) performed so far and their long-term extensions showed a comparable clinical efficacy of FIL to biologic treatments, with an acceptable safety profile. Thanks to these data, FIL was approved in Europe and Japan for the treatment of active RA, increasing the spectrum of therapeutic approaches and improving the possibility of a more tailored therapeutic strategy. Real-life data and head-to-head clinical trials will be needed to confirm its efficacy and safety.
Keyphrases
- phase ii
- clinical trial
- rheumatoid arthritis
- phase iii
- open label
- randomized controlled trial
- disease activity
- double blind
- electronic health record
- placebo controlled
- systemic lupus erythematosus
- optic nerve
- systematic review
- study protocol
- interstitial lung disease
- idiopathic pulmonary fibrosis
- drug administration